November 2023 — Monthly Briefing¶
1. What was read¶
834 research articles from 31 of the 33 journals on the roster.
A further 216 records (21% of the 1,050 this month's harvest returned) carry no abstract and are not research: news, correspondence, editor highlights and obituaries. PubMed types them Journal Article and nothing else, so the publication-type filter cannot see them — across the whole index they are 22.7% of it and 35% of general, and 3,801 of them are JAMA. Every count below is over the full harvest and is inflated by this; the figure above is not.
| General | Cancer | Immune | Bioinfo | Sysbio |
|---|---|---|---|---|
| 546 | 160 | 81 | 242 | 21 |
Largest contributors: Lancet 116, Nature 115, Science 102, JAMA 90, Nucleic Acids Res 82, Bioinformatics 66.
2. Net change on the thread curve¶
| Thread | This month | Cumulative | Status |
|---|---|---|---|
cell-therapy |
+5 / −2 | +78 / −23 | forming |
ctdna-mrd |
+1 | +22 / −12 | splitting |
foundation-models |
— | +28 / −15 | splitting |
immunotherapy-resistance |
+3 / −2 | +93 / −29 | forming |
interception |
+1 | +54 / −7 | forming |
method-credibility |
−4 | +2 / −117 | crisis |
neoantigen-vaccines |
+3 / −1 | +35 / −14 | forming |
neuro-immune-microbiome-axis |
+5 | +58 / −5 | forming |
next-gen-checkpoints |
+7 | +23 / −14 | splitting |
single-cell-3d-genome |
+1 | +21 / −6 | forming |
suppressive-population-inversion |
+1 / −3 | +23 / −26 | contested |
Status is derived by rule, not asserted. Fewer than 5 cards → too-early; then refutes ≥ 2×supports → crisis; refutes > supports → contested; supports ≥ 2×refutes → forming; else splitting.
3. The evidence that moved it¶
Nature reports glioma cells recruiting the brain's own machinery for adaptive plasticity (37914930). This is the strongest form the neuro-immune-microbiome-axis claim can take. The weak version says nerves modulate tumours; the strong version says the two are running one mechanism, and a tumour that co-opts synaptic plasticity — the process by which the host circuit learns — is not being modulated by the nervous system, it is participating in it. A tumour with a stake in circuit remodelling is also a tumour whose growth is coupled to what the patient's brain is doing, which is a different therapeutic object from a mass with nerves nearby.
Three groups reach tumour-associated microbes in one month, and two of them are fungal. Cancer Cell has the intratumoral mycobiome promoting lung cancer progression through myeloid-derived suppressor cells (37738973) and, separately, a named tumour-resident bacterium conferring chemoradiation resistance via a lactate-driven metabolic shift (37863066). Nature Immunology has fungal microbiota sustaining activation of neutrophils and their progenitors in severe COVID-19 (37872315) — the microbiome acting on host haematopoiesis rather than on local tissue. All three are causal mechanisms with a named organism and a named effector arm, which is what separates this month's microbiome evidence from the compositional-association literature it sits in.
Engineered cell therapy moves on three axes at once. Nature Medicine doses a CAR against a solid-tumour antigen in patients alongside an RNA vaccine that amplifies the product in vivo (37872225); Cell points engineered T cells at an autoantibody-defined B cell population in a neurological autoimmune disease (37918394); and Nature reports peptide-centric CARs against intracellular oncoproteins (37938771), with Immunity reaching the same class of target by a different route using dimeric IgA (37909039). Solid tumours, autoimmunity and the intracellular proteome are three distinct barriers, and the cell-therapy claim is precisely that the platform crosses them.
A non-PD-1 checkpoint reaches a clinical readout, and TIM-3 is worked on twice. Nature Medicine reports a phase 1 result for a molecule targeting both PD-1 and LAG-3 across solid and haematologic disease (37857711) — clinical-stage evidence the category mostly lacks, since most of its content is preclinical target nomination. On the nomination side, JITC puts a myeloid-restricted receptor forward as a checkpoint that improves anti-PD-1 in gastric cancer (37935567), and TIM-3 is attacked twice in two days by different groups and different modalities: antibody blockade in diffuse intrinsic pontine glioma (37802053) and a small-molecule inhibitor (37967204).
Interception's precursor layer gets measured in tissue and in blood. Nature Genetics runs two papers in the same issue on mosaic chromosomal alterations — a pan-tissue survey (37904053) and a whole-genome analysis across ancestries in blood (37904051) — establishing the clonal precursor state as something with population-scale structure rather than case reports. Blood reports a circulating protein elevated years ahead of a Hodgkin lymphoma diagnosis (37748137), which makes the same window accessible without a tissue sample.
4. Refutations¶
(a) Landing on a tracked thread¶
Science Immunology publishes two documented costs of removing a suppressive population, in the same month. Regulatory T cells are shown to shield muscle mitochondria from interferon-γ damage, which is how exercise produces its benefit (37922340); and CSF1R-dependent macrophages — the lineage most routinely nominated for depletion in tumours — turn out to be required for epithelial regeneration after radiation injury (37922341). The second is the more awkward for suppressive-population-inversion, because irradiated tissue is not a hypothetical setting: it is the tissue of the patients in whom myeloid depletion would be combined with radiotherapy. The thread's claim is that removing these populations improves antitumour outcomes; neither paper contradicts that directly, and both price it.
Two cell-therapy failure modes are created by the engineering rather than by the disease. Nature reports latent human herpesvirus 6 reactivating inside the manufactured T cell product itself (37938768). Nature Cancer reports acquired resistance to a T-cell engager against a new myeloma antigen through genetic or epigenetic inactivation of that target (37653140) — antigen escape following the platform to a fresh antigen rather than being a peculiarity of the one it started on.
JITC traces anti-PD-1 resistance in melanoma to a chromatin repressor acting inside the tumour cell on its own MHC class II (38315170), which is the tumour-intrinsic account immunotherapy-resistance claims is being displaced. And Immunity prints the neoantigen field's improvement and its limits together: machine learning with harmonised data raises immunogenicity prediction (37816353), and in the same issue an accompanying piece names the trade-offs the prediction step cannot escape (37967528). A journal contesting a claim within one issue is a better signal about the state of that claim than either paper alone.
(b) Method credibility¶
Genome Biology reports that a gene family in wide use is misannotated at scale — DNA transposons catalogued as a general transcription factor (37957683). This is the worst kind of failure for method-credibility, because the error is in the reference rather than in a tool: anything that looked the gene up inherits it, and nothing in a downstream analysis would reveal it.
A chromatin mark is being redefined across two journals in six weeks. Nature described acetyl-methyllysine marking chromatin at active transcription start sites in October (37731000); Nature Genetics now reports it as a dual modification of histone H4 (37938719). When a mark's identity is in motion, so is every dataset that assayed it — though two papers refining one modification is the ordinary way a mark gets characterised, and it is worth less than the misannotation above, where the error is already in the reference.
Corrected 2026-08-27
This paragraph ran to three journals, the third being a Science piece titled A case of mistaken epigenetic identity (37943909), which was read as a reassignment of the mark across the published record. The title is a pun. The paper's entire abstract is one sentence — "The specialized packaging of sperm DNA preserves genome stability in the fruit fly zygote" — and it is not about acetyl-methyllysine, about reproducibility, or about the reference at all. Its card has been withdrawn and carries no thread. Nothing in this month's method-credibility column depends on it.
Nature Genetics also shows that discovery of genetic effects on gene expression and on complex traits is systematically non-overlapping (37857933), with a companion framing the same result as a power paradox (37857936) — the routine practice of reading gene function off association statistics is biased by the study design, not by the biology. And Science publishes prediction-powered inference (37943906), a correction procedure for drawing valid conclusions when model predictions stand in for measurements. It belongs here because of what its existence concedes: without it, treating model output as data is invalid, and a great deal of published work does exactly that.
How to read the ratio¶
Eleven of this month's forty cards refute, and the quarter runs near forty per cent — above the corpus's established rate. That is a property of how these months were read, not of the months: the reading brief ranked refutations first and went looking for them. The reading was originally done against titles alone, so a stance was recorded only where the title stated it and papers that bury their conclusion were underrepresented regardless of quality. Those were recovered by an abstract re-scan on 2026-09-04. This month is the least title-hidden of 2023 — 25% against a year average of 59% — and it is also the month whose refutation share fell most on re-reading, from near forty per cent to the 28% above. And it was done in arrears. Each card is written to what its title supports in November 2023, but that is a discipline applied by hand rather than something the method enforces.
5. Open items¶
Nothing carried forward.
6. Meetings¶
2 abstracts from 1 meeting.
| Meeting | Abstracts | With full text |
|---|---|---|
| ASCO Annual Meeting 2023 | 2 | 2 |
7. Regulatory¶
| Event | Count |
|---|---|
| trial-first-posted | 462 (of which 400 genuinely oncology) |
| ema-authorisation | 8 |
| fda-approval | 7 |
7 FDA actions — dated from each notice's own prose, not the table's posting date, which disagrees on 7 of 190 rows and once by enough to move an approval into the wrong month:
- 2023-11-07 — FDA amends pembrolizumab’s gastric cancer indication
- 2023-11-08 — FDA approves fruquintinib in refractory metastatic colorectal cancer
- 2023-11-15 — FDA approves repotrectinib for ROS1-positive non-small cell lung cancer
- 2023-11-16 — FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence
- 2023-11-16 — FDA approves capivasertib with fulvestrant for breast cancer
- 2023-11-16 — FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma
- 2023-11-27 — FDA approves nirogacestat for desmoid tumors
4 EMA oncology authorisations:
- 2023-11-06 — Vanflyta
- 2023-11-15 — Herwenda
- 2023-11-15 — Finlee
- 2023-11-27 — Pylclari
8. Trade press¶
No items. The press archive covers 2024-01 to 2026-08; feeds that cannot be paginated backwards contribute only from the first harvest forward.